Life Sciences

Life Sciences

Treating Alzheimer´s disease by targeting Amyloid ß-nitration - A novel therapeutic/diagnostic/ prophylactic approach



Ref.-Nr. 2311

Part of the inflammatory response in Alzheimer´s disease (AD) is the upregulation of the inducible nitric oxide synthase NOS2 resulting in increased NO production. NO contributes to cell signaling by inducing posttranslational protein modifications. Under pathological conditions there is a shift to the formation of protein tyrosine nitration by secondary products like peroxynitrite and nitrogen dioxide.

The invention is based on the finding that amyloid β (Aβ) is nitrated at tyrosine 10 in AD-brains. Nitration accelerates its aggregation and is present in Aβ plaques. Injection of the nitrated protein into the brain of APP/PS1 transgenic mice leads to β-amyloidosis.

An antibody specific to the nitrated form of Aβ has been developed.
A therapeutic approach interfering with the nitrated Aβ (rather than with the native Aβ-peptide) may provide a very specific treatment with a reduced risk of side-effects.

Commercial Opportunities
The invention offers a novel approach for an early diagnosis of AD. The invention also opens new avenues for developing either NCEs or biologicals interfering with the nitrated Aβ. Antibody-based therapeutic approaches (e.g. passive/active vaccination) are currently been developed. Prophylactic approaches are also conceivable.

On behalf of University of Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.

Current Status  
Patent applications are pending in EP, US and Canada. Clinical trials with β-3NTyr10-antibodies are currently in preparation.

bitte Kontaktieren Sie mich zu diesem angebot.


PROvendis GmbH · Schloßstr. 11 – 15
D – 45468 Mülheim an der Ruhr
T +49 (0)208 94105-0 ·